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Abstract
Background: Clostridium difficile whole genome sequencing has the potential to identify related isolates, even among
otherwise indistinguishable strains, but interpretation depends on understanding genomic variation within isolates and
individuals.
Methods: Serial isolates from two scenarios were whole genome sequenced. Firstly, 62 isolates from 29 timepoints from
three in vitro gut models, inoculated with a NAP1/027 strain. Secondly, 122 isolates from 44 patients (2–8 samples/patient)
with mostly recurrent/on-going symptomatic NAP-1/027 C. difficile infection. Reference-based mapping was used to identify
single nucleotide variants (SNVs).
Results: Across three gut model inductions, two with antibiotic treatment, total 137 days, only two new SNVs became
established. Pre-existing minority SNVs became dominant in two models. Several SNVs were detected, only present in the
minority of colonies at one/two timepoints. The median (inter-quartile range) [range] time between patients’ first and last
samples was 60 (29.5–118.5) [0–561] days. Within-patient C. difficile evolution was 0.45 SNVs/called genome/year (95%CI
0.00–1.28) and within-host diversity was 0.28 SNVs/called genome (0.05–0.53). 26/28 gut model and patient SNVs were non-
synonymous, affecting a range of gene targets.
Conclusions: The consistency of whole genome sequencing data from gut model C. difficile isolates, and the high stability of
genomic sequences in isolates from patients, supports the use of whole genome sequencing in detailed transmission
investigations.
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Introduction
Multiple typing and fingerprinting schemes have been described
for the common healthcare-associated pathogen Clostridium difficile.
These have variable discriminatory power and practicality:
particularly regarding utility by non-specialist laboratories, avail-
ability of reference databases and cost. [1] We have recently
successfully applied sequence-based typing (multi-locus sequence
typing, MLST)[2–4] to the investigation of C. difficile transmission.
[5] This approach showed that the majority of 1282 C. difficile
infection (CDI) cases over 2.5 years could not be explained by
recent hospital ward contact with other symptomatic cases.
However, the dominance of epidemic C. difficile types in many
scenarios, for example ribotype 027 (NAP-1), [6,7] emphasises the
need for typing methods with high discriminatory power that can
be applied in multiple settings.
The increasing availability and affordability of next-generation
whole genome sequencing (WGS) technology offers much greater
genetic resolution that has hitherto been available.[8–10] Howev-
er, increased discriminatory power may be undermined by genetic
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instability. There is therefore a key need to understand the stability
of the C. difficile genome over time (ie its microevolution) in order
to maximise the potential value of WGS, since plausibility of
transmission between closely related isolates can only be
interpreted in the context of within-patient diversity at single
points in time, and over time. Ideally, such studies should use data
obtained from both controlled experimental and in vivo settings to
test the reproducibility of observations. Crucially, such combined
approaches offer the potential to examine the effects of interven-
tions/exposures. We have therefore investigated C. difficile genome
stability from successive samples recovered from a gut model that
simulates CDI and its treatment, [11,12] and from serial isolates
recovered from patients with on-going or recurrent CDI.
Materials and Methods
We collected C. difficile isolates from each of the following two
distinct sources. Firstly, serial samples were taken for whole
genome sequencing from 3 human gut CDI model experiments
conducted to investigate specific research questions.[12–14] One
model simulated CDI resulting from co-amoxiclav exposure
(without CDI treatment), and the other two, CDI following
clindamycin exposure, then subsequently treated either with
vancomycin for 4 days or cadazolid (a novel oxazolidinone/
quinolone hybrid [15]) for 7 days. The gut model used is described
in full elsewhere,[12–14] however, briefly, it consists of three
vessels in a weir cascade system, held under anaerobic conditions,
and designed to reflect the increasing alkalinity (pH 5.5–6.8) and
reduced substrate availability of the proximal to distal colon. In
each experiment the system was inoculated with a pooled faecal
slurry of C. difficile culture-negative faeces that were obtained from
five healthy (C. difficile negative) elderly ($60y) volunteers. The
model was top-fed with a growth medium at a controlled rate. The
following time periods key time periods were observed (Figure 1):
Period A, steady state, when the model was left to equilibrate for at
least two weeks prior to interventions; Period B, C. difficile spore
inoculation, when the model was instilled with ,107 cfu C. difficile
ribotype 027 spores and monitored for seven days; Period C, C.
difficile spore inoculation and CDI initiation, when the model was
instilled with a further ,107cfu C. difficile ribotype 027 spores and
CDI-provoking antibiotics (co-amoxiclav 8 mg/L, TID, 7d; or
clindamycin, 33.9 mg/L, QID, 7d); Period D, CDI, i.e. C. difficile
cytotoxin induction, following provocative antibiotic treatment;
Period E, In two of the three gut models, CDI treatment
(vancomycin 125 mg/L, QID 4d, or cadazolid 250 mg/L BID 7d
[14,15]) following high level cytotoxin production ($4 relative
units) for $2 days; and finally period F, a rest period when no
further interventions took place. C. difficile isolates were obtained
from the gut model at the timepoints indicated in Figures 2, 3, and
4, chosen to represent the different stages of C. difficile evolution
within the gut and the variation in antibiotic selection pressure.
Following culture on Columbia blood agar (ANO2, 24 h, 37uC).
DNA was extracted from sub-culture of a representative sweep
taken across the primary culture plate, except for 3 occasions
where 12 individual colonies were sub-cultured and DNA
extracted from the resulting growth to assess for within-‘host’
diversity (co-amoxiclav model, final timepoint and clindamycin/
vancomycin model immediately prior to CDI treatment and at the
final timepoint).
Secondly, we analysed whole genome sequences from C. difficile
cultured from 44 patients sampled more than once during on-
going or recurrent CDI due to C. difficile ribotype 027 (multi-locus
sequence type 1, ST1). These CDI cases were identified from
sequential unformed faecal samples that had been submitted to the
Oxford University Hospitals NHS Trust Microbiology laboratory
between September 2006 and March 2011 for routine investiga-
tion of microbial causes of diarrhoea. The cases build upon an
existing collection of whole genome sequences from serially
sampled patients which included 28 ribotype 027 infections which
were previously analysed together with 63 other samples. [16] C.
difficile toxin enzyme immunoassay (Meridian Biosciences, Cin-
cinnati, OH) positive samples were cultured following an alcohol-
shock on modified Brazier’s cycloserine-cefoxitin-egg yolk agar.
[2] Culture positive isolates underwent MLST. [2] DNA was
extracted from sub-culture of a single colony from each positive
clinical sample.
DNA samples were prepared for sequencing using standard
Illumina (San Diego, California, USA) and adapted protocols.
Pools of 96 samples were sequenced at the Wellcome Trust Centre
for Human Genetics, Oxford, UK, using sequencing-by-synthesis
technology, [17] on the Illumina Genome Analyzer II (GAII),
GAIIx, and HiSeq platforms, generating 50–108 base pair reads.
Sequence reads were mapped using Stampy v1.0.11 (without
Burrows-Wheeler Aligner pre-mapping, using an expected substi-
tution rate of 0.01) [18] to a ribotype 027 C. difficile reference
genome, CD196 (Genbank: FN538970) [19], to produce BAM
files used in subsequent base-calling. Single nucleotide variants
(SNVs) were identified across all mapped non-repetitive sites using
SAMtools (version 0.1.12–10) [20] mpileup with the extended
base-alignment quality flag, after parameter tuning based on
bacterial sequences (options ‘-E -M0 -Q30 -q30 -m2 -D –S’). To
identify repetitive regions, BLAST [21] searches of the CD196
reference genome were made using fragments of the same
genome. As all strains analysed in this study were the same
lineage as the reference strain (ribotype 027), we did not mask
mobile elements. We only used SNVs that were supported by $5
reads, including one in each direction. A consensus of $75% was
also required to support a SNV, and calls had to be homozygous
under a diploid model.
As a quality control, five isolates had DNA extracted twice, and
were sequenced twice, producing indistinguishable final sequences.
The within-host diversity and rate of C. difficile evolution was
estimated by maximum likelihood from first and last isolates from
serially sampled patients under a coalescent model [22] assuming a
Poisson distribution for the accumulation of mutations (see Text
S1). Confidence intervals were obtained by parametric bootstrap.
dN/dS ratios were calculated using the Nei and Gojobori method.
[23] Genomes were sampled with replacement 1000 times to
generate bootstrap confidence intervals.
Ethical approval for use of patient samples without individual
consent was provided by the Oxford Research Ethics Committee
(10/H0505/83) and the National Information Governance Board
(8-05(e)/2010).
Results
Genomic Stability of C. difficile Gut Model Isolates
A total of 62 C. difficile isolates were obtained and successfully
sequenced from 29 samples collected from 3 gut models: 18
isolates from the co-amoxiclav induction model (7 timepoints over
35 days, 12 isolates at last timepoint, figure 2), 33 isolates from the
clindamycin induction, vancomycin treatment model (11 time-
points over 70 days, 12 isolates at two timepoints, just prior to, and
following vancomycin treatment, figure 3), and 11 isolates from
the clindamycin/cadazolid model (11 timepoints over 32 days,
figure 4). A mean 90.3% of the CD196 reference genome was
called, with a mean read depth of 62.3.
C. difficile Short-Term Genome Stability
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A total of 10 variable sites were identified across all 3 gut models
(figures 2, 3, and 4). Both the co-amoxiclav and clindamycin-
vancomycin models were inoculated with the same C. difficile
ribotype 027 isolate. Sequences obtained from whole culture plate
sweeps at the first 2 timepoints in these models show evidence of
heterozygousity at 3 of the variant sites in both experiments (sites
1592378, 2916358, 3391317) suggesting that a mixture of C.
difficile with and without these SNVs was present in the initial
inoculum. In the co-amoxiclav model one of these SNVs
(2916358) persisted throughout and was present in 7 of the 12
colonies sequenced at the final timepoint. In contrast the
proportion of reads containing the other 2 SNVs diminished
during the population expansion associated with CDI cytotoxin
induction (phase D), and were present in 0/12 and 1/12 colonies
at the end of the model. In the clindamycin/vancomycin model, 2
of the pre-existing SNVs became established (sites 1592378,
2916358), as well as a new SNV which arose during induction and
persisted during treatment (2206108). In both models, a number of
minority variants emerged, evidence of which could be seen in
multiple picks taken following CDI cytotoxin induction (co-
amoxiclav model, sites 9921 and 10179; clindamycin/vancomycin
model, site 977041) and CDI treatment (clindamycin/vancomycin
model, 2380323, 3493190) (figures 2b, 3b). In the final model,
clindamycin/cadazolid, a single SNV was observed at the final 2
timepoints (2914411) following treatment.
Overall, over a total 137 days of follow up, including three CDI
inductions and two CDI treatments, only two new SNVs emerged
that became established in the majority of sequences. Pre-existing
SNVs present in the minority of the within-model inoculum
population became dominant twice in one model, and once in
another. Five additional SNVs were detected that were only
present in the minority of colonies at one or two timepoints.
Genomic Stability of C. difficile Patient Isolates
A total of 122 isolates were obtained from 122 faecal samples
from 44 patients with mostly recurrent, or on-going, CDI due to C.
difficile ribotype 027/ST1 (23 patients with 2 samples, 12 patients
with 3 samples, 8 patients with 4 samples and 1 patient with 8
samples). The median (IQR, range) time between first and last
samples was 60 (29.5–118.5, 0–561) days. A single patient with 20
SNVs between first and last samples taken 60 days apart was
excluded because the subsequent sample was considered more
likely to represent a re-infection, as there was no evidence of a
single recombination, no SNVs in DNA mismatch repair genes,
and a sequence matching the later sample had previously been
found in several other patients admitted to an adjacent ward at the
same time. In the remaining 43 patients, successive C. difficile
isolates from 28 patients had no SNVs. A further 3 patients had
isolates with transient SNVs that were not detected at the final
timepoint: 2 had a single SNV, and the other had 13 SNVs
distributed throughout the genome after 93 days; in the latter case,
however, the isolate recovered from a sample collected on the
following day was identical to the initial isolate, suggesting a mixed
infection in the transient 13 SNV isolate. The remaining patients
had isolates with 1 SNV (n= 7), 2 SNVs (n= 4) or 3 SNVs (n= 1)
(Figure 5a) at the final timepoint. All SNVs were distinct from
those observed in the gut model. The overall rate of evolution
estimated from first and last samples from these 43 serially
sampled patients was 0.42 SNVs/year (95% CI 0.00–1.30) in the
sites routinely called by sequencing (mean 90.0% of the CD196
reference genome) (Figure 5b). The within-patient diversity was
0.28 SNVs/called genome (95% CI 0.04–0.54). Excluding a single
out-lying point at 561 days with 0 SNVs in a sensitivity analysis,
the rate of evolution was 0.75 (95%CI 0.00–1.87)/called genome/
year and the within-patient diversity 0.16 SNVs/called genome
(95%CI 0.00–0.46).
Functional Impact of Variants
The functional impact of SNVs arising in the gut model isolates
and serial sample isolates from infected patients is shown in table 1.
Nine of the 10 SNVs across the three gut models occurred within
an annotated coding sequence, and all resulted in a non-
synonymous change, including two causing a premature stop
codon. Similarly 19 of the 21 SNVs from patient samples occurred
in coding sequence, with only 2 resulting in synonymous changes,
and the remainder non-synonymous, including 4 premature stop
codons. No patients developed the same SNV independently.
There was only one occurrence of the same gene being affected by
two mutations, both occurring in a RNA polymerase sigma-B
factor gene in the co-amoxiclav induction gut model. Transcrip-
tion and transport/metabolism pathways were affected by non-
synonymous SNVs in both clinical and gut model isolates.
Discussion
We have demonstrated using isolates obtained from two
complimentary sources, recurrent CDI in patients and a predictive
experimental gut model of CDI, that there is a high degree of C.
difficile genome stability as measured by WGS. The two
investigated scenarios represented opportunities for C. difficile
genome mutation occurring over periods of one to several months.
The studied settings represent relatively controlled and uncon-
Figure 1. Gut model samples. A schematic diagram of the gut model experiments to induce and treat Clostridium difficile infection. CD,
Clostridium difficile. CDI, C. difficile infection. Cfu, colony forming units.
doi:10.1371/journal.pone.0063540.g001
C. difficile Short-Term Genome Stability
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trolled stresses that could be expected to increase the chance of
SNV occurrence. Both yielded isolates from CDI symptomatic/
toxin production periods and after treatment.
Both the gut model and clinical patient isolates showed evidence
of within host variation at the initial sample, either directly in the
case of the gut model, or from the evolutionary model in the
clinical samples. This contributed significantly to SNV differences
observed between baseline and subsequent samples. The 2 new
SNVs observed over 137 days of gut model follow up are
consistent with the estimates for C. difficile evolution of 0.42 (95%
CI 0.00–1.30) SNVs/sampled genome/year obtained from serially
sampled patients. The relatively broad confidence interval,
encompassing zero, reflects the limited number of recurrent
ribotype 027 infections in our dataset, and is a limitation of our
study. When a single outlier with zero SNVs after 561 days was
removed, the estimated rate of evolution increased modestly to
0.75 (95%CI 0.00–1.87) SNVs/called genome/year. This high-
lights the potential difficulties in applying a single clock rate to C.
difficile, as the prolonged time with zero SNVs could represent time
spent dormant in a spore state with a slower rate of evolution,
which would lower the overall estimated rate of evolution. The
estimates obtained are similar to previous estimates where data
from ribotype 027 and non-ribotype 027 samples were combined.
[16].
The presence of minority variants detected by sequencing sub-
cultures of multiple colonies, whilst not unexpected, is a reminder
that diversity may be detected between transmitted cases as a
result of sampling a minority variant in either the donor or the
recipient. Similarly, if only a single colony is sub-cultured,
potential mixed infection may also be missed. However sequencing
Figure 2. Co-amoxiclav induction gut model samples and variable site base counts. Panel A shows the total viable counts, spore counts
and cytotoxin titres. Sampling points are shown as circles. Sampling points where 12 colonies were sub-cultured and sequenced separately are
shown with an *. Panel B shows the base counts obtained at the variable sites identified between sequences. Each sample is represented in a
different column. Samples taken at different timepoints are numbered sequentially. Where 12 colonies were sub-cultured at a given timepoint these
are indicated by different letters following the sample number and yellow background shading. Replicate samples sequenced to assess the accuracy
of the sequencing are shown with a‘, e.g. 3’ and blue background shading. The proportion of high quality (base quality PHRED scaled score $30,
mapping quality $30) base counts supporting the SNV identified is shown for each variable site as a separate row. Median (range) calls per site 49
(23–99). No site with .2 different base calls.
doi:10.1371/journal.pone.0063540.g002
C. difficile Short-Term Genome Stability
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Figure 3. Clindamycin-induction, vancomycin-treatment gut model samples and variable site base counts. Panel A shows the total
viable counts, spore counts and cytotoxin titres. Sampling points are shown as circles. Sampling points where 12 colonies were sub-cultured and
sequenced separately are shown with an *. Panel B shows the base counts obtained at the variable sites identified between sequences. Each sample
is represented in a different column. Samples taken at different timepoints are numbered sequentially. Where 12 colonies were sub-cultured at a
given timepoint these are indicated by different letters following the sample number and yellow background shading (pre-treatment) and purple
background shading (post-treatment). Replicate samples sequenced to assess the accuracy of the sequencing are shown with a‘, e.g. 6c’ and blue
background shading. The proportion of high quality (base quality$30, mapping quality$30) base counts supporting the SNV identified is shown for
each variable site as a separate row. Median (range) calls per site 71 (28–198). No site with .2 different base calls.
doi:10.1371/journal.pone.0063540.g003
C. difficile Short-Term Genome Stability
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sweeps of primary culture plates using existing data pipelines may
also miss minority variants if these are attributed to sequencing
error, or result in a heterozygous base calls, which may be
converted to a null call by sequencing quality filtering algorithms.
Therefore, sequencing the full diversity present on primary culture
plates together with bioinformatic approaches specifically designed
to detect mixed infection may provide an optimal approach [24].
While relatively few mutations were observed, a striking
proportion were non-synonymous. Twenty-six of 28 SNVs in
coding regions were non-synonymous, with 6 resulting in
premature truncation of a gene. This corresponds to a dN/dS
ratio (ratio of non-synonymous vs. synonymous substitution rate,
adjusted for the redundancy in the codons affected) of 5.3 (95% CI
1.6 to ‘), which contrasts with the dN/dS ratio reported in
another whole genome study of recently diverged C. difficile
lineages of very close to 1. [25] However the genomes in this
previous study were separated by up to several years, rather than
several weeks as was typical in our study. Although dN/dS ratios
above 1 are suggestive of SNVs arising in response to selective
pressure, such as might be experienced during antibiotic exposure,
short-term ratios are typically higher owing to a lag in the removal
of slightly deleterious mutations. [26] A number of transient SNVs
were also observed, consistent with genetic drift. Whilst the
classification of genes with SNVs is intriguing, with SNVs arising
after antibiotic exposure in genes involved in transcription and
transport/metabolism pathways, much larger formal association
studies are required to understand their functional significance.
Another limitation of our study is that we do not have details of
the specific interventions, particularly treatments, for individual
CDI cases. However, during the study hospital policy was to treat
initial CDI and first recurrence with oral vancomycin for 14 days;
treatment was initiated when samples were sent for C. difficile
testing and compliance was high (data not shown). Where patient’s
first and subsequent samples were more than 14 days apart (63 of
the 78 subsequent samples obtained), we have assumed that these
represent recurrences of CDI (in these cases, relapses with the
same strains), or possibly failure to respond to initial treatment in
some patients. Given the prolonged observation periods, it is
highly likely that some of the strains we have examined were
subjected to multiple exposures to antibiotics used to treat CDI
and possibly other infections, and this could be explored in more
detail in future studies. In common with the patients studied, CDI
treatment with vancomycin was also simulated in one of the gut
models. Whilst it would also be of interest to repeat the study in a
population receiving metronidazole treatment (not used in
Oxfordshire hospitals), and to simulate metronidazole treatment,
the consistency of the results obtained to date suggest that this
would be unlikely to materially alter our findings. The antibiotic
used to treat simulated CDI in the final gut model is a hybrid
Figure 4. Clindamycin-induction, cadazolid-treatment gut model samples and variable site base counts. Panel A shows the total viable
counts, spore counts and cytotoxin titres. Sampling points are shown as circles. Panel B shows the base counts obtained at the variable sites
identified between sequences. Each sample is represented in a different column. Samples taken at different timepoints are numbered sequentially.
Replicate samples sequenced to assess the accuracy of the sequencing are shown with a‘, e.g. 6’ and blue shading. The proportion of high quality
(base quality$30, mapping quality$30) base counts supporting the SNV identified is shown for each variable site as a separate row. Median (range)
calls per site 57 (28–89). No site with .2 different base calls.
doi:10.1371/journal.pone.0063540.g004
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molecule, which is currently in phase II clinical trials for the
treatment of CDI. [14,15].
Recombination and hypermutation are two ways in which the
modest rate of genome mutation we observed here could in theory
accelerate. Hypermutation is not well studied in C. difficile. In this
study, we found no variant sites arising within annotated DNA
mismatch repair enzymes, responsible for hypermutation de-
scribed in Staphylococcus aureus [27] and other pathogens. [28]
There is clear evidence for recombination in the C. difficile genome
over longer timescales, [3,16,25] although interestingly it is not
seen as frequently in ribotype 027 isolates compared to some other
lineages. [16] With relatively few variants and short time scales we
did not find evidence of clustering of nearby variable sites
suggestive of recombination in our study. However, the absence of
Figure 5. Observed single nucleotide variants between serially sampled patients with ST1/ribotype 027 CDI. Panel A shows each
patient as a separate horizontal line. Samples were obtained from each patient at the start and end of each line, any additional intermediate samples
obtained are shown with a ‘x’. Twenty-eight patients with no SNVs at any timepoint are shown at the top of the plot. The 16 patients with at least 1
SNV observed at $1 timepoint are lettered A to P. SNVs are shown as black circles, the number corresponding to table 1. ` indicates a patient with
13 transient SNVs, observed after 93 days, and with a sample indistinguishable from baseline at 94 days. 1 indicates a patient with 20 SNVs
presumed to be a re-infection, and excluded from panel B. Panel B shows the time between first and last samples from 43 serially sampled
patients. The line indicates a coalescent-based model for the rate of C. difficile evolution fitted by maximum likelihood assuming a Poisson
distribution for the accumulation of mutations. 95% confidence intervals obtained by parametric bootstrap are shown shaded.
doi:10.1371/journal.pone.0063540.g005
C. difficile Short-Term Genome Stability
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C. difficile mixed infection in the gut model precludes within-species
recombination.
Our data showing relatively stable genomes, and low but non-
zero microevolution, in the face of interventions and indeed
repeated episodes of infection and treatment provide reassurance
that WGS can be used to (re-) examine the epidemiology of C.
difficile and aetiology of CDI. For example, using genotyping
(MLST) we recently unexpectedly found that about three-quarters
of CDI cases could not be linked to other cases by ward-based
contact, [5] raising the issue of other sources of C. difficile
transmission not well addressed by current infection control policy
and guidance. Whole genome sequence data offer the potential to
study such C. difficile transmission in more detail. [16] To interpret
WGS data, however, it is necessary to first establish the ‘natural’
rate of genome mutation. Without such microevolutionary
information, use of such a highly discriminatory fingerprinting
method risks dismissing CDI cases and sources that could in fact
be related. [9] Speculation about the aetiology of community CDI
cases and indeed the possible links between human and animal C.
difficile strains emphasise the need for optimised fingerprinting
studies. [29,30] A better understanding of other possible routes of
transmission and reservoirs is needed to optimise control efforts.
In summary, the consistency of sequences from our gut model
isolates demonstrates the reliability of our sequencing and analysis
techniques. Crucially, the high stability of mapped genomic
sequences in C. difficile isolates from patients supports their use in
detailed transmission studies. Our findings also highlight the
importance of detailed microevolutionary studies specific to key
pathogens to maximise the future value of pathogen whole
genome sequencing.
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